Table 1. Study characteristics included in meta-analysis of SVR12 rate among HCV-infected patient with advanced chronic kidney disease.
| First author/year | Country | No. of patients | Recruitment period | Mean Age (SD) | Cirrhosis N(%) | No. of patient on dialysis/Total patient | SVR12 | SVR24 | NOS score |
|---|---|---|---|---|---|---|---|---|---|
| Taneja 2018 [24] | India | 65 | 2016 | 49 (13) | 21 (32.3%) | (54/65) | 100 | _ | 6 |
| Surendra 2018 [25] | India | 19 | 2016 | 44 | 0 | (19/19) | 100 | _ | 6 |
| Manoj 2018 [26] | India | 71 | 2015–2017 | 42 | 17 (23.9%) | (11/71) | 100 | 98.5 | 6 |
| Akhil 2018 [16] | India | 22 | 2015–2016 | 49.8 | 0 | (22/22) | 100 | _ | 6 |
| Sperl 2017 [27] | Czech Republic | 6 | 2015–2016 | 39 | 2 (33.3%) | (6/6) | 100 | _ | 5 |
| Dumortier 2017 [28] | France | 50 | 2013–2015 | 60.5 (7.5) | 0 | (35/50) | 86 | _ | 6 |
| Cox-North 2017 [29] | USA | 29 | 2014–2016 | _ | 13 (44.8%) | (0/29) | 97 | _ | 6 |
| Choudhary 2017 [30] | India | 16 | 2015–2016 | 45 (12) | 2 (12.5%) | (16/16) | 80 | _ | 6 |
| Aggarwal 2017 [31] | USA | 14 | _ | 61 (4.9) | 12 (85.7%) | (14/14) | 92.8 | _ | 6 |
| Agarwal 2017 [32] | India | 62 | 2015–2016 | 33.8 (10.2) | 3 (4.8%) | (62/62) | 95.2 | _ | 6 |
| Singh 2016 [33] | USA | 8 | 2014–2015 | 56.8 (20) | 3 (37%) | (8/8) | 100 | _ | 6 |
| Saxena 2016 [34] | USA | 18 | _ | ≥65 | - | - | 88 | _ | 8 |
| Nazario 2016 [35] | USA | 17 | _ | 57 | 8 (47%) | (17/17) | 100 | _ | 6 |
| Desnoyer 2016 [36] | France | 12 | 2014–2015 | 52 | 10 (83.4%) | (12/12) | 83.3 | 100 | 6 |
| Beinhardt 2016 [37] | Austria | 10 | _ | 50.6 (10.9) | 4 (40%) | (10/10) | 96 | 96 | 8 |
| Hundemer 2015 [38] | USA | 6 | 2014 | 60 (14) | 3 (50%) | (6/6) | 64 | _ | 6 |
| Goel 2018 [39] | India | 41 | 2015–2017 | 41 | 5 (12%) | (41/41) | 90.2 | _ | 6 |
| Gupta 2018 [40] | India | 7 | 2015–2016 | 48.8 ± 14.5 | 2 (28.6%) | (7/7) | 100 | _ | 6 |
| Mehta 2018 [41] | India | 38 | 2016 | 49.5 | _ | (26/26) | 100 | _ | 6 |
| 92.3 | |||||||||
| Borgia 2019 [42] | Canada, the United Kingdom, Spain, Israel, New Zealand, and Australia | 59 | 2017–2018 | 60 | 17 (29%) | (59/59) | 95 | _ | 6 |
| Poustchi 2020 [43] | Iran | 103 | 2017–2018 | 50.3±13.5 | 39 (37.9%) | (75/103) | 100 | _ | 6 |
| Eletreby 2020 [44] | Egypt | 579 | 2014–2018 | 52 | 107 (11%) | 10/579 | 96.7 | _ | 8 |
| Debnath 2020 [45] | India | 18 | 2017–2018 | 39.4 ± 8.3 | 0 | 18/18 | 100 | _ | 6 |
| Michels 2020 [46] | Brazil | 34 | 2016–2017 | 60.7±10.4 | 0 | 34/34 | 99.3 | 97.1 | 8 |
| Cheema 2019 [47] | Pakistan | 18 | 2017–2018 | 47.2±14.1 | 4 (22.2%) | 18/18 | 83.3 | 83.3 | 8 |
| Mandhwani 2020 [48] | Pakistan | 133 | 2016–2018 | 31.9 ± 9.8 | 0 | 133/133 | 96.9 | _ | 8 |
| Seo 2020 [49] | Korea | 9 | 2017–2018 | 59.9 | 2 (22.2%) | 9/9 | 100 | _ | 6 |